{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:58:03Z","timestamp":1780394283152,"version":"3.54.1"},"reference-count":29,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background: Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of mature T-cell lymphoma, accounting for fewer than 5% of peripheral T-cell lymphomas, with an aggressive course and poor prognosis. There are two types of this disease based on morphology and immunophenotype: type I, which is often, but not always, associated with celiac disease (classic EATL), and type 2, monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL). Risk factors for classic EATL are poor adherence to a gluten-free diet, advanced age, male sex, and HLA-DQ2 homozygosity. The treatment options include surgery and various chemotherapy regimens with autologous stem cell transplantation, but the outcomes are discouraging, and clinical trials with targeted and biologic therapies are needed. Case Presentation: We report three cases of type 1 EATL, all with lethal outcomes, with one patient dying during initial treatment, one dying following several surgical interventions and without waiting to start chemotherapy, and one dying following a good treatment response but with severe infection.<\/jats:p>","DOI":"10.3390\/hematolrep17050043","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:43:16Z","timestamp":1756366996000},"page":"43","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Case-Based Insights into Enteropathy-Associated T-Cell Lymphoma\u2014Single-Center Experience"],"prefix":"10.3390","volume":"17","author":[{"given":"Marija","family":"Elez","sequence":"first","affiliation":[{"name":"Clinic of Hematology, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinika","family":"Atanaskovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Mirosavljevi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1938-8298","authenticated-orcid":false,"given":"Mihailo","family":"Bezmarevi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for General Surgery, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"\u017divojinovi\u0107","sequence":"additional","affiliation":[{"name":"Institute for Pathology, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslav","family":"Romanovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Urgent Internal Medicine, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Djeki\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Predrag","family":"Krsti\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2011-02-335216","article-title":"Enteropathy- associated T cell Lymphoma: Clinical and histological findings from the International Peripheral T-Cell Lymphoma Project","volume":"118","author":"Delabie","year":"2011","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1053\/j.gastro.2005.02.027","article-title":"Association of celiac disease and intestinal lymphomas and other cancers","volume":"128","author":"Catassi","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1136\/bmj.293.6552.908","article-title":"Humoral response to wheat protein in patients with celiac disease and enteropathy associated T cell lymphoma","volume":"293","author":"Feighery","year":"1986","journal-title":"Br. Med. J."},{"key":"ref_4","first-page":"2458","article-title":"How I treat enteropathy-associated T-cell lymphoma","volume":"119","author":"Biagi","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1080\/00365520802240222","article-title":"Incidence of enteropathy associated T cell lymphoma: A nation-wide study of population based registry in The Nederlands","volume":"43","author":"Verbeek","year":"2008","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/modpathol.2015.85","article-title":"Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan","volume":"28","author":"Tomita","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_7","first-page":"806","article-title":"Monomorphic Epitheliotropic Intestinal T-cell Lymphoma: A Study of Four Cases and Review of Literature","volume":"50","author":"Fei","year":"2020","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11899-021-00634-4","article-title":"Enteropathy- Associated T cell Lymphoma","volume":"16","author":"Hamadani","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of WHO Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.5858\/arpa.2013-0242-CR","article-title":"Classic Versus Type II Enteropathy- Associated T-Cell Lymphoma: Diagnostic Considerations","volume":"137","author":"Arps","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.clml.2023.05.012","article-title":"SOHO State of the Art Updates and Next Questions|Challenging Cases in Rare T-Cell Lymphomas","volume":"23","author":"Bhansali","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23992","article-title":"Treatment response in enteropathy associated T cell lymphoma: Survival in large multicenter cohort","volume":"90","author":"Nijeboer","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kronsten, V.T., Gosson, C., Al-Khatib, A., Bagwan, I., Worthington, T., Muthalali, S., Ethell, M., Lim, G., and Youd, P. (2022). Tonsillar Extraintestinal Enteropathy- Associated T- Cell Lymphoma in a Patient With Celiac Disease. ACG Case Rep. J., 9.","DOI":"10.14309\/crj.0000000000000824"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2141.2006.06371.x","article-title":"Combination chemotherapy followed with autologous stem cell transplantation for enteropathy- associated T cell lymphoma","volume":"136","author":"Bishton","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11899-011-0097-7","article-title":"Enteropathy- Associated T Cell Lymphoma: Epidemiology, Clinical Features and Current Treatment Strategies","volume":"6","author":"Sieniawski","year":"2011","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double- blind, randomized, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as firstline treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2008.07202.x","article-title":"Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma","volume":"142","author":"Soldini","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3748\/wjg.v17.i4.506","article-title":"Evaluation of cladribine treatment in refractory celiac disease type II","volume":"17","author":"Tack","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/hon.13_2881","article-title":"Intestinal T-Cell Lymphomas: Molecular Integrative Analysis Recognizes Different Therapeutic Targets for Each Subtype","volume":"39","author":"Manso","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gooderham, M.J., Forman, S.B., Bissonnette, R., Beebe, J.S., Zhang, W., Banfield, C., Zhu, L., Papacharalambous, J., Vincent, M.S., and Peeva, E. (2020). Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial. JAMA Dermatol., 156.","DOI":"10.1001\/jamadermatol.2019.2855"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3892\/ijo.2016.3806","article-title":"Bortezomib induces apoptosis and suppresses cell growth and metastasis by inactivation of Stat3 signaling in chondrosarcoma","volume":"50","author":"Bao","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2468-1253(19)30265-1","article-title":"Safety and efficacy of AMG 714 in patients with type 2 refractory celiac disease: A phase 2a, randomized, double-blind, placebo-controlled, parallel-group study","volume":"4","author":"Cellier","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bpg.2009.11.002","article-title":"Enteropathy associated T-cell Lymphoma and its precursor lesions","volume":"24","author":"Cillessen","year":"2010","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1136\/gut.52.8.1211","article-title":"Small bowel neoplasia in celiac disease","volume":"52","author":"Rampertab","year":"2003","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4251\/wjgo.v13.i9.1017","article-title":"Association between intestinal neoplasms and celiac disease: A review","volume":"13","author":"Wang","year":"2021","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Almasri, M., Maher, N., Al Deeban, B., Diop, N.M., Moia, R., and Gaidano, G. (2025). Liquid Biopsy in B and T cell Lymphoma: From Bench to Bedside. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104869"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/5\/43\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:33:43Z","timestamp":1760034823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/5\/43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["hematolrep17050043"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep17050043","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}